[{"orgOrder":0,"company":"SpineThera","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"SpineThera","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Epidural Injection","sponsorNew":"SpineThera \/ Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"SpineThera \/ Department of Defense"},{"orgOrder":0,"company":"SpineThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SpineThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SpineThera \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SpineThera \/ Not Applicable"},{"orgOrder":0,"company":"SpineThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"SpineThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"SpineThera \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SpineThera \/ Not Applicable"},{"orgOrder":0,"company":"SpineThera","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"SpineThera","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"SpineThera \/ Mayo Clinic","highestDevelopmentStatusID":"1","companyTruncated":"SpineThera \/ Mayo Clinic"}]

Find Clinical Drug Pipeline Developments & Deals by SpineThera

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : The collaboration aims to develop long-acting injectable drugs to improve treatment outcomes for individuals with substance abuse disorders using it’s novel, long-acting injectable technology.

Brand Name : Undisclosed

Molecule Type : Undisclosed

Upfront Cash : Undisclosed

June 17, 2024

Lead Product(s) : Undisclosed

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Undisclosed

Sponsor : Mayo Clinic

Deal Size : Undisclosed

Deal Type : Collaboration

blank

02

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : SX600 (dexamethasone) is a novel formulation of extended-release microspheres designed for transforaminal epidural injection in the management of sciatica pain.

Brand Name : SX600

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 06, 2023

Lead Product(s) : Dexamethasone

Therapeutic Area : Musculoskeletal

Highest Development Status : Phase I/ Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : SX600, is novel formulation of dexamethasone acetate microspheres for micro-suspension injection, was designed as a targeted, extended-release corticosteroid with the potential to demonstrate a substantially improved profile relative to radicular leg pai...

Brand Name : SX600

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 07, 2022

Lead Product(s) : Dexamethasone

Therapeutic Area : Neurology

Highest Development Status : Phase I/ Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : The scope of work supported by this grant award includes nonclinical toxicity testing of SX600 and manufacturing process development and scale-up activities. Together, these activities will position SX600 for future Phase 3 clinical trials.

Brand Name : SX600

Molecule Type : Small molecule

Upfront Cash : Undisclosed

April 26, 2022

Lead Product(s) : Dexamethasone

Therapeutic Area : Musculoskeletal

Highest Development Status : Phase I/ Phase II

Sponsor : Department of Defense

Deal Size : $5.0 million

Deal Type : Funding

blank